Works matching IS 21641153 AND DT 2023 AND VI 13 AND IP 3
Results: 18
New Oncology Drugs, New Indications, and New Formulations Approved by the FDA.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 167
- Publication type:
- Article
Preclinical and Early Clinical Data Show Promising Antitumor Activity With the HER2 Inhibitor ZN-1041 in Patients With Breast Cancer and Brain Metastases.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 166
- Publication type:
- Article
Dalpiciclib Plus Pyrotinib and Endocrine Therapy Shows Promising Antitumor Activity in ER-Positive, HER2-Positive Metastatic Breast Cancer.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 165
- Publication type:
- Article
Phase 1b/2 Trial of Ribociclib, Tucatinib, and Trastuzumab to Find Chemotherapy-Free Treatment Combination Regimens for HER2-Positive Breast Cancer.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 164
- Publication type:
- Article
Strong Antitumor Activity With Neoadjuvant Intratumoral Dendritic Cell Vaccine Therapy Plus Paclitaxel, Trastuzumab, and Pertuzumab in HER2-Positive Breast Cancer.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 163
- Publication type:
- Article
Anti-HER2/HER3 αDC1 Vaccines Plus Pembrolizumab for Brain Metastases in Patients With Triple-Negative or HER2-Positive Breast Cancer.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 162
- Publication type:
- Article
Neratinib Plus Trastuzumab Emtansine in Patients With HER2-Positive Breast Cancer and Molecular Residual Disease.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 161
- Publication type:
- Article
Dalpiciclib Plus Pyrotinib Prolongs Survival in Patients With HER2-Positive Advanced Breast Cancer.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 160
- Publication type:
- Article
Inetetamab Plus Camrelizumab and Utidelone Safe and Effective in Patients With HER2-Positive Metastatic Breast Cancer.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 159
- Publication type:
- Article
Prolonged Effectiveness With Tucatinib Plus Trastuzumab and Capecitabine in HER2-Positive Metastatic Breast Cancer.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 158
- Publication type:
- Article
Zanidatamab Plus Docetaxel Shows Promising Antitumor Activity in Advanced HER2-Positive Breast Cancer.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 157
- Publication type:
- Article
Successful Extended At-Home Olaparib Desensitization After a Hypersensitivity Reaction: A Case Report.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 153
- By:
- Publication type:
- Article
Clinical and Financial Impacts of an Ambulatory Oncology Pharmacist-Based Intravenous Chemotherapy Education and Follow-Up Program.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 146
- By:
- Publication type:
- Article
Stopping Oral Chemotherapy Agents With a High Bleeding Risk Before and After Minor Surgical Procedures.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 140
- By:
- Publication type:
- Article
Retrospective Evaluation of Initial Empiric Double Coverage With Tobramycin in Adult Patients With Febrile Neutropenia.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 133
- By:
- Publication type:
- Article
Incidence of Infusion-Related Reactions With Pertuzumab and Ado-Trastuzumab Emtansine: A Retrospective Study.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 128
- By:
- Publication type:
- Article
To the Editor.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 126
- By:
- Publication type:
- Article
JHOP Editorial Board Member, Readers, and Author Interact: Optimizing the Administration of Daratumumab.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 125
- By:
- Publication type:
- Article